entertainment -WSS

entertainment

author：fashion 2025-10-03 00:07:35 - browse：617

Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the longtime and polarizing director Alex Denner would step down from its board, sending a signal to investors that the company’s fractious recent history might be coming to a close.

What Biogen didn’t disclose is that its nominee to replace Denner on the board, Susan Langer, is Denner’s live-in romantic partner and the mother of his child, born in November, according to court records obtained by STAT. Denner is in the middle of a protracted divorce from his wife of nearly 25 years, with whom he has two teenage sons — a bitter legal fight in which his extramarital relationship with Langer is a contentious issue, according to the records.

Biogen spokesperson Jack Cox said the company knew about the relationship between Denner and Langer. He also said that Denner recommended Langer to Biogen’s board — he said he incorrectly stated at first that Denner nominated her — but declined to comment on the company’s vetting process and whether it planned to disclose the relationship to shareholders before they vote on Langer’s candidacy later this month. Biogen also omitted mention of the relationship from Langer’s biography in a Securities and Exchange Commission filing Tuesday morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： The FDA weighs the risks of candy

WSS

Meta's Zuckerberg and Chan on track to put $50 billion into science

Take antibiotics after sex, CDC recommends for certain risk groups

Why Sanofi got shellacked over its spinoff

WHO may add ‘noma' to its list of neglected tropical diseases

Maker of FluMist seeks to allow at

WHO may add ‘noma' to its list of neglected tropical diseases

focus

entertainment

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Wildfire smoke exposes gaps in outdoor worker protections

Emergency medicine has repudiated 'excited delirium.' Now what?

United colonoscopy coverage change 'may cost lives,' doctors say

Physician subsidies by hospitals soar in wake of No Surprises Act

Hepatitis C has a cure — but many Americans still lack access to it

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: XBI biotech index, Akero Therapeutics

focus

Elevance PBM president out as customers face prescription chaos

CDC recommends rationing of RSV shot due to shortages

How CO2 helps viruses stay alive longer in the air

WHO may add ‘noma' to its list of neglected tropical diseases

Testing for cancer recurrence creates a new limbo for patients

Data don't support strong claims for Covid

leisure time

hotspot

knowledge

leisure time